Question explored with the scientific record
Conversation so far
- 1 Stage 0 melanoma in a mole vs not in mole
- 2 Stage 0 melanoma in a mole vs not in mole life expectancy difference
- 3 Stage 0 melanoma life expectancy difference
- 4 Stage 0 melanoma life expectancy when from 60 years
Answered on this page ↓
Stage 0 melanoma life expectancy when from 60 years
The short version: age 60 at diagnosis doesn't change what stage 0 is, and nothing in this evidence measures life expectancy by age at diagnosis. What it does show is that the cancer itself is very unlikely to be what kills you.
Stage 0 means the abnormal cells are still in the top layer of skin. The treatment is removal, and the survival figures here are for melanoma in situ treated surgically: 92% with Mohs and 94% with wide excision at five years [1]. Those are overall survival numbers in people whose average age was 64 and 58.5 respectively [1] — close to your 60. Most of those deaths are from other causes at that age, not from the stage 0 lesion.
The honest gap: no record here follows a 60-year-old cohort and reports life expectancy. The 92% and 94% are five-year figures, not lifetime projections [1]. And a meaningful share of lesions called stage 0 turn out to have invasive cells once fully excised — the prior turn's 23% figure is not in this block, so treat it as carried over, not re-verified.
| Group | Mean age | 5-year survival | Recurrence |
|---|---|---|---|
| Mohs surgery | 64.0 [1] | 92% [1] | 1.8% [1] |
| Wide local excision | 58.5 [1] | 94% [1] | 5.7% [1] |
My call: at 60, a stage 0 melanoma diagnosis is very unlikely to shorten your life, and the surgical choice barely moves five-year survival [1]. Confidence: moderate on the direction, low on any specific life-expectancy number, because no record here provides one.
Sources used 1
-
Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision
This study compares the outcomes of melanoma in situ treated with Mohs micrographic surgery versus wide local excision, finding no significant differences in recurrence rates or survival outcomes.
DOI: 10.1001/jamadermatol.2016.6138